Hemogenyx Pharmaceuticals Share Discussion Threads

[purple11] 18/3/2020 09:44

I agree.its not looking good is it.

[marie1980_m] 18/3/2020 09:23

What a useless thread this is

[on target] 18/3/2020 09:14

Time for the other board members to put their hands in their pocket and buy some shares in their own company.
Show us this isn't a scam lifestyle company for the Dr.

[purple11] 18/3/2020 08:45

4.9mcap now

[purple11] 18/3/2020 07:37

bye marie.

and dummy accounts don't count.sadly you didn't make anything.

[waterloo01] 18/3/2020 07:16

Noted some mention of humanised mice being used in COVID trials. No idea of anything to do with HEMO

[marie1980_m] 18/3/2020 04:22

Hahaha John
I think if someone show you mirror is no good.
I can’t help myself but I m in so much profit . Almost like 190% in ETF

but again won’t invest here in scam company lol

I just want to see reaction from Purple.

I’m sure he will be super disappointed with my huge profit and my best market reaction which I can understand.

Marie is the one and only one ;)

[marie1980_m] 17/3/2020 23:13

You can block me if you’ve no conscience.

On target, I read your mesage.

Yes HEMO is a scam company.
Doesn’t trust me ? Wait for 1 more year:

It’s not rocket science to understand

[marie1980_m] 17/3/2020 23:08

Block me If you’ve conscience Purple

[marie1980_m] 17/3/2020 22:58

Purple,

I’m genuinely sorry for you and others who doesn’t understand the pattern

[purple11] 16/3/2020 12:20

no sellers at 1.20 thankgod.

what can we expect the whole markets collapsing.

[johntopdog] 16/3/2020 11:57

Share price collapsing !!

[on target] 16/3/2020 11:22

Quite right, we don't want Hemogenyx-related posts on this thread.

[tullynessle] 14/3/2020 16:03

Re Post 1329

I Googled :

"Neutralizing antibodies against emerging pathogens are going mainstream, Hemogenyx"

And the following article appeared on the first page, noting that the search indicated that the words "Neutralizing" and "Mainstream" were excluded.





Proactive

Hemogenyx develops new mouse model which could play a big role in future wars

08:26 Mon 24 Jun 2019

Hemogenyx thinks its new ApbHC mouse model could be used to rapidly develop antibodies to treat deadly pathogens such as Anthrax released as an act of war

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has developed a new generation of humanised mice which it believes could play a vital role in protecting people caught up in biological warfare.

Governments spend billions of dollars every year protecting their citizens from the threat of biological weapons, such as the release of pathogens and toxins including anthrax and smallpox.

Hemogenyx thinks its new mouse model, called Advanced peripheral blood Hematopoietic Chimera (ApbHC), could potentially be used to help rapidly develop treatments against unknown human-specific pathogens.

ApbHC has “several advantages” over other mouse models, says Hemogenyx, including the absence of Graft versus Host disease – when the mouse rejects the transplanted tissue – which makes the use of certain cells impossible.

Article continues.......

[tullynessle] 14/3/2020 15:31

Purple Post 1327

1328 prepared concurrently with your 1327.

I agree with your thoughts that Lilly may be the global co partner?

I suppose there has to be some reasons for Hemogenyx to highlight the News Release, although it many be as simple as general interest in medical/research process, progress in managing the pandemic, or reference to "Neutralizing antibodies against emerging pathogens are going mainstream."

[tullynessle] 14/3/2020 15:25

Hemogenyx highlighted the Lilly News Release in its tweet, however not sure which component of the research / discovery process is similar to Hemogenyx technology, (if any).

I noticed that the document mentions that "our goal with AbCellera is to be testing potential new therapies in patients within the next four months." so that appears to be good news.





03/12/2020

AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-

VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.

Within one week of receiving a blood sample from one of the first U.S. patients who recovered from COVID-19, AbCellera screened over 5 million immune cells looking for ones that produced functional antibodies that helped the patient neutralize the virus and recover from the disease. From this effort, AbCellera has identified over 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoV-2 antibodies ever reported. The next step is to screen these antibodies to find the ones most effective in neutralizing SARS-CoV-2. Many of these antibodies will be expressed in collaboration with partners at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and pending agreement with NIAID will be tested for their ability to neutralize the virus.

"AbCellera's platform has delivered, with unprecedented speed, by far the world's largest panel of anti-SAR-CoV-2 antibodies," said Carl Hansen, Ph.D., CEO of AbCellera. "In 11 days, we've discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world's leading biopharmaceutical companies. We're deeply impressed with the speed and agility of Lilly's response to this global challenge. Together, our teams are committed to delivering a countermeasure to stop the outbreak."

"With the number of cases rapidly increasing all over the world, doctors and patients are seeking a therapeutic intervention that can speed their recovery or prevent the disease. Lilly is committed to playing our part to bring innovation to patients amidst this global outbreak," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "We've partnered with AbCellera because we're impressed with the speed and quality of their efforts. We are moving at top speed to create a potential treatment to help patients. While typically a new therapeutic antibody program might take years to get in the clinic, our goal with AbCellera is to be testing potential new therapies in patients within the next four months."

Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution. If successful, Lilly is ready to work with global regulators to bring a treatment to patients.

==============================


Hemogenyx
@HemoGenyx
·
4h
Neutralizing antibodies against emerging pathogens are going mainstream.

[purple11] 14/3/2020 15:09

hemogenyx tweeting about lilly.is this the global co partner?






Hemogenyx

@HemoGenyx


Neutralizing antibodies against emerging pathogens are going mainstream.



AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 | Eli Lilly and...
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

investor.lilly.com